Argatroban in the management of heparin-induced thrombocytopenia: A multicenter clinical trial

Abstract

Introduction: The aim of this study was to collect data in France in patients with heparin-induced thrombocytopenia who required parenteral anticoagulation and for whom other non-heparin anticoagulant therapies were contraindicated including patients with renal failure, cross-reactivity to danaparoid or at high hemorrhagic risk. Methods: A total of 20 patients, of mean age 72±10years, were enrolled in this open-label, multicenter clinical study. Exploratory statistical data analysis was performed with descriptive interpretation of intra-individual comparisons using simple univariate statistics. Results: The diagnosis of HIT was confirmed in 16 subjects by an independent scientific committee. Fourteen patients (70%) were in an intensive care unit during the course of the study. Patients were treated with argatroban for a mean duration of 8.5±6.1days. The mean starting dose of argatroban was 0.77±0.45μg/kg/min. Platelet recovery was rapid. aPTT and anti-IIa activity assays were used to monitor the dose of argatroban. The mean baseline aPTT value was 45.0±9.8sec and increased to 78.2±35.8sec two hours after initiating argatroban. At this time mean argatroban concentration was 0.34±0.16 and 0.61±0.28μg/ml using ECT and TT measurements, respectively. New and/or extended thromboses were reported in 25% of patients and major bleedings were documented in 15%. Six patients died due to their underlying medical condition. Conclusion: Considering its hepatic elimination and its short half-life, argatroban can be considered as a safe therapeutic option in HIT patients at high hemorrhagic risk and with renal failure, particularly in an ICU setting.